Gritstone bio Inc (GRTSQ)

[Renee]

GRTS changed to GRTSQ, bankruptcy. Delisted from the Nasdaq to the OTC: ***pps dropped 41% from .047 to .0278 on 58 million volume.

https://otce.finra.org/otce/dailyList?viewType=Additions

[Disquisition]

IMMENSE DUMPING

[Disquisition]

DELISTING DUMPING

[TrendTrade2016]

THIS STOCK GETS DELISTED OR SPLIT...NO WAY OUT...B ECAREFUL WITH NASDAQ BIOS UNDER A DOLLAR...OR ANY FOR THAT MATTER.......HOWEVER WACH TOMORROW...IS THERE ANOTHER VTEK COMING...JUST MAYBE.... STAY TUNED!!!
SOMEONE ASKED ME ABOUT THIS STOCK, ONLY REASON TO POST.

[Arnold25764]

What price was the offering?

[Disquisition]

UNREPENTANT DUMPING

[Disquisition]

CONTINUOUS SELLING

[tw0122]

.0789 + 40%

[glenn1919]

GRTS.............................https://stockcharts.com/h-sc/ui?s=GRTS&p=W&b=5&g=0&id=p86431144783

[Disquisition]

BANKRUPTCY DUMPING

[bigfart]

bankrupt

[Dennis14]

https://stockcharts.com/h-sc/ui RSI is at 22

[Dennis14]

Funny part 16 million buys to 12 million sells 2 million neutral.

[Disquisition]

UNBELIEVABLE DUMPING

[jondoeuk]

Including neoantigens for recognition by CD4+ T-cells greatly improved the effectiveness, while tumour-unrelated CD4+ T-cell antigens did not https://www.cell.com/molecular-therapy-family/oncology/fulltext/S2950-3299(24)00077-8

[jondoeuk]

Still the only company I'm aware of that is able to induce such a rapid, robust and consistent large number of CD8+ T-cells.



But having a strong CD8+ T-cell response is useless without the right selection https://www.science.org/doi/10.1126/scitranslmed.aax7918

EDGE does not specifically model immunogenicity but performs reasonably well at predicting immunogenic peptides (immunogenicity is >50% of mutations per patient generate a detectable CD8+ T-cell response).

CD4+ T-cell responses are important as well (but prediction is a lot harder) https://www.nature.com/articles/s41586-019-1671-8

Also, what setting it is given is equally important. They (vaccines in general) likely offer a greater benefit to the patient if administered in earlier clinical settings, such as the adjuvant setting, for a number of reasons.

[Monksdream]

GRTS new 52 lo

[Tom turtles]

And then the offering....classic bs

[DewDiligence]

GRTS—(-40%/AH)—reports purportedly-positive interim phase-2 data:

https://www.globenewswire.com/news-release/2024/04/01/2855416/0/en/Gritstone-bio-Announces-Positive-Preliminary-Progression-free-Survival-and-Long-term-Circulating-Tumor-DNA-ctDNA-Data-from-Phase-2-Portion-of-Ongoing-Phase-2-3-Study-of-its-Persona.html

Gritstone bio…today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC).

Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms.

Emphasis added.

[jondoeuk]

The results could be difficult to interpret as Gritstone is primarily evaluating ctDNA, an endpoint that doesn't have the full backing from any regulator that I know of. Gritstone could also report other data, but the company argues that radiographic endpoints aren't as good as ctDNA, which means that the endpoints might not match up.

[Little Run]

Yep, looking past $3 now…let’s ride!!!😎🍻🍻✌️

[TrendTrade2016]

grts breaking 2.75 trigger

[TrendTrade2016]

GRTS...NEXT STOP 2.75

[TrendTrade2016]

GRTS MONSTER CANCER PLAY

[TrendTrade2016]

GRTS WHAT A MONSTER...LETS SEE 2.46 NEXT

[TrendTrade2016]

GRTS....READY FOR 2.32

[Little Run]

That’s next…

[TrendTrade2016]

GRTS...I THINK THEY CURED CANCER

[TrendTrade2016]

GRTS READY FOR 2.37

[RT2GAIN]

Merry Christmas $$$

[Monksdream]

GRTS under $2

[Little Run]

Wow, finally some company. LOL!!! Oncology side is even stronger. Barda $$$ was great though. LFG!!!

[crudeoil24]

Gritstone Bio shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7. >>>>> GRTS <<<<<
Benzinga

[RT2GAIN]

I wonder how many people know that this is a cornovavirus stock company… hmmm

[RT2GAIN]

Sounds like you're keeping a close eye on this one. Hoping for the best!

[Wolf of MP]

This is just the appetizer. Shorties going to get roasted once float locks up. Lots of shares sold at these levels. Longs or quick flippers should be rewarded soon

[TrendTrade2016]

GRTS..BREAKING NICELY

[RT2GAIN]

Merry Christmas $$$

[Wolf of MP]

They are trying for that cup and handle. Let's goo

[Wolf of MP]

Getting up for the next leg. Get in or get left behind.

All IMO of course. Trading well, should be trading much better with a $400 mil grant. I suspect some manipulation to take all the shares they can get.

[TrendTrade2016]

GRTS ANOTHER BIO READY

[crudeoil24]

Share price holding in AH . Let's see how she runs tomorrow.

[crudeoil24]

Maybe government grants don't count in totaling yearly revenues ! > $$$$$

[TheFinalCD]

WE ARE LIKE

underpaid news reporters

https://finviz.com/quote.ashx?t=GRTS&p=d

[sc00pnDump]

Barely anyone is selling, and the shorts disappeared…..



Wow, looks good for tomorrow


Have a great night

[sc00pnDump]

Latest News

UPDATE 1-Gritstone bio wins $433
million US contract for COVID vaccine study
Sep 27, 2023 at 4:48 p.m. ET
(Adds share price and study details in paragraphs 3-5)
Sept 27 (Reuters) - Gritstone bio on Wednesday secured a $433 million contract by the U.S. government to conduct a mid-stage study of its self-amplifying mRNA COVID-19 vaccine candidate.
The contract is a part of "Project NextGen," an initiative by the U.S. Department of Health and Human Services to advance a pipeline of new, innovative vaccines and therapeutics providing broader and more durable protection against COVID-19 infection.
Gritstone's shares rose 36.1% to $1.61 after the bell.
The study will compare the efficacy, safety and immunogenicity of Gritstone's COVID-19 vaccine candidate with an approved vaccine.
Gritstone plans to initiate the mid-stage study in the first quarter of next year.
The contract was awarded by the Biomedical Advanced Research and Development Authority, a U.S. federal agency that funds disease-fighting technology.

[weedtrader420]

WOOHOOOOOO WOOHOOOOOO

[weedtrader420]

Looks like that’s going to change

[crudeoil24]

Horrible Revenues > According to MarketWatch, GRTS annual revenue averages $11,000. per employee.

[crudeoil24]

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates by vaccine vectors, self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens, peptides that are presented on cancer cells when certain mutations occur in tumor DNA.